

Financial news for FCSC dated on 2019-09-16: 56 Biggest Movers From Friday

Financial news for FCSC dated on 2019-09-13: Mid-Afternoon Market Update: Park City Falls Following Q4 Results; MER Telemanagement Solutions Shares Climb

Financial news for FCSC dated on 2019-09-13: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for FCSC dated on 2019-09-13: Mid-Day Market Update: Vince Holding Surges After Q2 Results; Ritter Pharmaceuticals Shares Slide

Financial news for FCSC dated on 2019-09-13: Mid-Morning Market Update: Markets Mostly Higher; Fibrocell Receives Cash Bid From Castle Creek Pharma

Financial news for FCSC dated on 2019-09-13: 24 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for FCSC dated on 2019-09-13: Fibrocell Spikes 60% After Receiving Cash Bid From Castle Creek Pharma

Financial news for FCSC dated on 2019-09-13: 24 Stocks Moving in Friday's Pre-Market Session

Financial news for FCSC dated on 2019-09-13: Fibrocell Science shares are trading higher after the company announced it will be acquired by Castle Creek Pharmaceutical for an all-cash consideration of \$3 per share.

Financial news for FCSC dated on 2019-09-13: A Peek Into The Markets: US Stock Futures Surge Ahead Of Economic Reports

Financial news for FCSC dated on 2019-09-13: 5 Stocks To Watch For September 13, 2019

Financial news for FCSC dated on 2019-09-12: Fibrocell Science To Be Acquired By Castle Creek Pharmaceutical For All-Cash Consideration Of \$3/Share

Financial news for FCSC dated on 2019-08-15: 26 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for FCSC dated on 2019-08-15: 28 Stocks Moving in Thursday's Pre-Market Session

Financial news for FCSC dated on 2019-08-15: The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

Financial news for FCSC dated on 2019-08-15: Fibrocell Science shares are trading higher after the company reported Q2 EPS results up from last year.

Financial news for FCSC dated on 2019-08-14: Fibrocell Science Q2 EPS \$1.12 Up From \$(0.49) YoY, Sales \$21.792M

Financial news for FCSC dated on 2019-05-30: 64 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-05-29: 42 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FCSC dated on 2019-05-29: Fibrocell Science shares are trading higher after the company received FDA regenerative medicine advanced therapy designation for FCX-007 Gene Therapy for the treatment of RDEB.

Financial news for FCSC dated on 2019-05-29: Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation For FCX-007 Gene Therapy For The Treatment Of RDEB

Financial news for FCSC dated on 2019-05-15: Fibrocell Science Q1 EPS \$(0.4) Misses \$(0.35) Estimate

Financial news for FCSC dated on 2019-04-23: 45 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-04-22: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for FCSC dated on 2019-04-17: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for FCSC dated on 2019-04-17: 40 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-04-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., Apr. 16, 2019

Financial news for FCSC dated on 2019-04-16: 44 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-04-15: Mid-Afternoon Market Update: Crude Oil Down 0.6%; Fibrocell Science Shares Spike Higher

Financial news for FCSC dated on 2019-04-15: Fibrocell Strikes Funding Deal For Gene Therapy Candidate

Financial news for FCSC dated on 2019-04-15: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for FCSC dated on 2019-04-15: Mid-Day Market Update: Electronics for Imaging Surges Following Acquisition News; Reebonz Shares Plummet

Financial news for FCSC dated on 2019-04-15: Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Posts Mixed Q1 Results

Financial news for FCSC dated on 2019-04-15: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for FCSC dated on 2019-04-15: A Peek Into The Markets: US Stock Futures Mixed After Goldman Sachs Earnings

Financial news for FCSC dated on 2019-04-15: Fibrocell Science shares are trading higher after the company announced an agreement with Castle Creek Pharmaceuticals to develop and commercialize FCX-007. Fibrocell will receive a \$30 million upfront payment.

Financial news for FCSC dated on 2019-04-15: UPDATE: Fibrocell is Developing FCX-007 With Intrexon and Will Pay Intrexon 50% of Upfront, Milestone and Profit Share Payments from Castle Creek Pharma

Financial news for FCSC dated on 2019-04-15: Fibrocell Announces Collaboration with Castle Creek Pharma to Develop and Commercialize FCX-007, Fibrocell to Receive Up to \$30M in Upfront Payments

Financial news for FCSC dated on 2019-03-28: 71 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-03-27: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FCSC dated on 2019-03-27: Mid-Day Market Update: Crude Oil Down Over 1%; Syndax Pharmaceuticals Shares Spike Higher

Financial news for FCSC dated on 2019-03-27: Mid-Morning Market Update: Markets Edge Lower; Centene To Buy Health Insurer Rival WellCare

Financial news for FCSC dated on 2019-03-27: 31 Stocks Moving In Wednesday's Pre-Market Session

Financial news for FCSC dated on 2019-03-27: UPDATE: Fibrocell Says FDA Provided Guidance On Various Design Aspects Of Co.'s Proposed Phase 3 Trial

Financial news for FCSC dated on 2019-03-27: Fibrocell Reports Feedback From Type B End-Of-Phase 2 Meeting With FDA On Phase 3 Trial Design For FCX-007

Financial news for FCSC dated on 2019-03-27: Earnings Scheduled For March 27, 2019

Financial news for FCSC dated on 2019-03-25: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for FCSC dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for FCSC dated on 2019-03-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for FCSC dated on 2019-03-20: Fibrocell Science shares are trading higher after the company announced it will host a conference call for 2018 results on March 27; the CEO will also discuss its recent end-of-Phase 2 meeting with the FDA and provide data for its ongoing Phase 1/2 trial.

Financial news for FCSC dated on 2019-03-20: Fibrocell Shares Rebound From \$2.20 Level After Testing Below Near-Term Support/Resistance Level; Spike ~25% Higher, Now Flirting With \$2.60 Level; Co. Earlier Announced Will Report FY18 Results On Mar. 27, 2019

Financial news for FCSC dated on 2019-03-14: 68 Biggest Movers From Yesterday

Financial news for FCSC dated on 2019-01-22: A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings

Financial news for FCSC dated on 2019-01-22: 10 Stocks To Watch For January 22, 2019

Financial news for FCSC dated on 2019-01-18: Fibrocell Science Reports 443.35K Share Common Stock Offering By Selling Shareholders

Financial news for FCSC dated on 2018-12-11: Fibrocell Receives \$900K Investment From EB Research Partnership And Epidermolysis Bullosa Medical Research Foundation

Financial news for FCSC dated on 2018-11-13: FIBROCELL SCIENCE Q3 EPS \$(0.28) Beats \$(0.60) Estimate

Financial news for FCSC dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for FCSC dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for FCSC dated on 2018-10-25: Fibrocell Receives Guidance From FDA OPn Phase 3 Clinical Trial Design For FCX-007; Co. Plans To Submit Phase 3 Protocol To FDA In Q4 Of 2018 And Commence Trial In First Half Of 2019

Financial news for FCSC dated on 2018-09-25: Fibrocell Awarded \$1.4M FDA Orphan Grant For FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2018-09-24: Fibrocell Science Shares Up 10.6%, Hearing Traders Attributing Strength To Unconfirmed Chatter of an FDA Contract

Financial news for FCSC dated on 2018-09-05: Fibrocell Announces FDA Fast Track Designation For FCX-013

Financial news for FCSC dated on 2018-08-10: Stocks Which Set New 52-Week Low Yesterday, August 9th

Financial news for FCSC dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for FCSC dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for FCSC dated on 2018-08-09: Fibrocell Science Q2 EPS \$(1.03) Misses \$(0.42) Estimate

Financial news for FCSC dated on 2018-08-01: Stocks Which Set New 52-Week Low Yesterday, July 31

Financial news for FCSC dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for FCSC dated on 2018-07-31: 50 Biggest Movers From Yesterday

Financial news for FCSC dated on 2018-07-30: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for FCSC dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for FCSC dated on 2018-07-03: 44 Biggest Movers From Yesterday

Financial news for FCSC dated on 2018-07-02: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for FCSC dated on 2018-07-02: Fibrocell Announces ~1.47M Share Registered Direct Offering Priced At-the-Market For Gross Proceeds Of ~\$4M

Financial news for FCSC dated on 2018-06-25: 50 Biggest Movers From Friday

Financial news for FCSC dated on 2018-06-22: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for FCSC dated on 2018-06-22: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for FCSC dated on 2018-06-22: 56 Biggest Movers From Yesterday

Financial news for FCSC dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for FCSC dated on 2018-05-31: Sabby Management Reports New 8.81% Stake In Fibrocell Science

Financial news for FCSC dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, ImmuteP Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for FCSC dated on 2018-05-30: 42 Biggest Movers From Yesterday

Financial news for FCSC dated on 2018-05-29: fibrocell Shares Down 11.5% After Co. Earlier Announced \$6M Registered Direct Offering Priced At-the-Market

Financial news for FCSC dated on 2018-05-29: Mid-Afternoon Market Update: Crude Oil Down 2.5%; American Woodmark Shares Spike Higher

Financial news for FCSC dated on 2018-05-29: 37 Stocks Moving In Tuesday's Mid-Day Session

Financial news for FCSC dated on 2018-05-29: Mid-Morning Market Update: Markets Open Lower; Booz Allen Hamilton Profit Beats Estimates

Financial news for FCSC dated on 2018-05-29: Fibrocell Announces \$6.0M Registered Direct Offering Priced At-the-Market

Financial news for FCSC dated on 2018-05-25: Benzinga's Weekly Movers For The Week Of May 25, 2018

Financial news for FCSC dated on 2018-05-24: Fibrocell Science Reports 1-For-5 Reverse Stock Split Will Be Effective Beginning Of Trade Fri., May 25 '18

Financial news for FCSC dated on 2018-05-21: Benzinga Pro's Top 10 Most-Searched Tickers For Evening Of Mon., May 21, 2018

Financial news for FCSC dated on 2018-05-21: Benzinga Pro's 5 Stocks To Watch Today

Financial news for FCSC dated on 2018-05-21: Fibrocell Give an Interim Update on Phase 1/2 Trial of FCX-007, Says Well Tolerated, Continued 'Positive' Trends

Financial news for FCSC dated on 2018-05-18: Fibrocell Science Shares Down 17.7% On Heavy Volume And No Apparent News After Spiking On Thursday; Co. Will Present On Interim Data For FCX-007 Phase I Trial Tomorrow

Financial news for FCSC dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for FCSC dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for FCSC dated on 2018-05-10: Fibrocell Science Q1 EPS \$(0.11) Beats \$(0.17) Estimate

Financial news for FCSC dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for FCSC dated on 2018-04-18: Fibrocell Sciences Shares Resume Trade, Now Up 5%

Financial news for FCSC dated on 2018-04-18: Fibrocell Sciences Shares To Resume Trade At 8:30 a.m. EDT

Financial news for FCSC dated on 2018-04-18: Fibrocell Reports Review of Strategic Alternatives

Financial news for FCSC dated on 2018-04-18: Fibrocell Science Shares Halted News Pending

Financial news for FCSC dated on 2018-03-19: Fibrocell Reports FY EPS \$(1.33) Beats \$(1.63) Est.

Financial news for FCSC dated on 2018-03-19: Earnings Scheduled For March 19, 2018

Financial news for FCSC dated on 2018-03-16: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for FCSC dated on 2018-03-06: Fibrocell Science Shares Up 4.4% After Announcing NDA for FCX-013

Financial news for FCSC dated on 2018-03-06: Fibrocell Announces FDA Allowance of an Investigational NDA for FCX-013 for Scleroderma

Financial news for FCSC dated on 2018-02-05: Fibrocell Announces Submission of Investigational New Drug Application for FCX-013

Financial news for FCSC dated on 2018-01-30: Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007

Financial news for FCSC dated on 2017-12-07: Fibrocell Prices \$10.5M Offering at \$0.77/Share and Warrant

Financial news for FCSC dated on 2017-12-07: Fibrocell Reports Pricing of \$10.5M Public Offering

Financial news for FCSC dated on 2017-11-28: 45 Biggest Movers From Yesterday

Financial news for FCSC dated on 2017-11-13: Fibrocell Reports Q3 EPS \$(0.02) vs \$(0.38) Est., No Sales

Financial news for FCSC dated on 2017-11-06: Fibrocell Science S-1 Filing Shows Registration For \$23M Common Stock Offering

Financial news for FCSC dated on 2017-09-26: Fibrocell Says Interim Phase 1/2 Data for FCX-007 Show it is Well Tolerated

Financial news for FCSC dated on 2017-09-08: 10 Biggest Mid-Day Gainers For Friday

Financial news for FCSC dated on 2017-08-09: Fibrocell Science Reports Q2 EPS \$(0.97) vs \$(0.55) In Same Qtr. Last Year

Financial news for FCSC dated on 2017-06-12: Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013

Financial news for FCSC dated on 2017-05-10: Fibrocell Science Reports Q1 EPS \$(0.60) vs \$(0.29) Est.

Financial news for FCSC dated on 2017-05-08: Fibrocell Reports Data Safety Monitoring Board Recommended Continuation of Phase 1/2 Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2017-03-10: Fibrocell Reports One-for-Three Reverse Stock Split

Financial news for FCSC dated on 2017-03-09: Fibrocell Reports FY16 EPS \$(0.39) vs \$(0.85) in FY15, Sales \$355K vs \$492K in FY15

Financial news for FCSC dated on 2017-03-07: Benzinga's Top Upgrades, Downgrades For March 7, 2017

Financial news for FCSC dated on 2017-03-07: Rodman & Renshaw Initiates Coverage On Fibrocell Science at Buy, Announces \$2.00 Price Target

Financial news for FCSC dated on 2017-02-23: Fibrocell Reports Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy

Financial news for FCSC dated on 2017-01-05: Fibrocell Announces FDA Fast Track Designation of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2017-01-05: Fibrocell Reports FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2016-12-19: Fibrocell Announces Leadership Changes John Maslowski Succeeds David Pernock as Chief Executive Officer

Financial news for FCSC dated on 2016-12-02: Fibrocell Science, Inc.: Pernock David (Director, Chairman and CEO) Buys 50,000 @ Avg Price: \$0.92 (Form4)

Financial news for FCSC dated on 2016-11-03: Fibrocell Reports Q3 EPS \$(0.05) vs. Est. \$(0.15), Rev. \$215K vs. Est. \$90K

Financial news for FCSC dated on 2016-09-19: Fibrocell Complete Enrollment of NC1+ Trial

Financial news for FCSC dated on 2016-08-09: There Have Been 20 Secondary Offerings Over The Last 2 Days

Financial news for FCSC dated on 2016-08-08: Fibrocell Announces Proposed Public Offering of Common Stock and Warrants

Financial news for FCSC dated on 2016-08-04: Fibrocell Reports Q2 EPS \$(0.18) vs

\$(0.15) Est., Sales \$73K vs \$70K Est.

Financial news for FCSC dated on 2016-07-27: Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007

Financial news for FCSC dated on 2016-06-30: Fibrocell TO Wind-Down azficel-T Operations And Reduce Workforce By 24 Positions, Will Incur \$0.3-\$0.4M Charge

Financial news for FCSC dated on 2016-06-28: 7 Biggest Mid-Day Losers For Tuesday

Financial news for FCSC dated on 2016-06-13: Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2016-06-08: Mid-Afternoon Market Update: Oil Rises Above \$51; Fibrocell Science Shares Tumble

Financial news for FCSC dated on 2016-06-08: 7 Biggest Mid-Day Losers For Wednesday

Financial news for FCSC dated on 2016-06-08: Mid-Day Market Update: VeriFone Drops Following Earnings Miss; Ashford Hospitality Prime Shares Surge

Financial news for FCSC dated on 2016-06-08: Fibrocell Plunges 40% After Second Stage azficel-T Trial Fails To Meet Primary Endpoints

Financial news for FCSC dated on 2016-06-08: Stocks Hitting 52-Week Lows

Financial news for FCSC dated on 2016-06-08: Mid-Morning Market Update: Markets Open Higher; Lululemon Reports Mixed Q1 Results

Financial news for FCSC dated on 2016-06-08: Shares of Fibrocell to Resume Trade at 8:30 a.m. EDT

Financial news for FCSC dated on 2016-06-08: Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints, No Unexpected Safety Findings and Treatment Well Tolerated

Financial news for FCSC dated on 2016-06-08: Fibrocell Science Shares Halted News Pending

Financial news for FCSC dated on 2016-05-24: Roth Resumes Coverage On Fibrocell With Buy Rating, \$7 Target

Financial news for FCSC dated on 2016-05-05: Fibrocell Reports Q1 EPS \$(0.08) vs \$(0.15) Est.

Financial news for FCSC dated on 2016-04-25: Fibrocell Reports Received Orphan Drug Designation from FDA for FCX-013 for Treatment of Localized Scleroderma

Financial news for FCSC dated on 2016-04-21: Fibrocell Expects Primary Endpoint Results In Q2 2016

Financial news for FCSC dated on 2016-04-18: Fibrocell, Intrexon Report Allowance to Begin Phase I/II Trial of FCX-007 for Treatment of RDEB

Financial news for FCSC dated on 2016-03-10: Fibrocell Reports Q4 EPS \$(0.40) vs \$(0.17) Est.

Financial news for FCSC dated on 2016-01-04: UPDATE: Fibrocell, Intrexon to Develop Treatment for Arthritis, Related Conditions Through Targeted, Long-term Therapeutic Delivery While Sparing Systemic Effects

Financial news for FCSC dated on 2016-01-04: Fibrocell, Intrexon Report Collaboration for Addressing Inflammatory, Degenerative Diseases of Joint

Financial news for FCSC dated on 2015-12-22: Roth Capital Initiates Coverage on Fibrocell Science at Buy, Announces \$14.00 PT

Financial news for FCSC dated on 2015-12-17: The Top 20 Wall Street Analysts Of 2015

Financial news for FCSC dated on 2015-11-05: Fibrocell Sciences Reports Q3 EPS \$(0.07) vs \$(0.16) Est.

Financial news for FCSC dated on 2015-10-08: Fibrocell, Intrexon Report Poster Presentation on FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa at American Society of Human Genetics Annual Meeting

Financial news for FCSC dated on 2015-09-28: Benzinga's Top Downgrades

Financial news for FCSC dated on 2015-09-28: Wedbush Cuts Fibrocell Science To Neutral

Financial news for FCSC dated on 2015-09-28: Wedbush Downgrades Fibrocell Science to Neutral, Lowers PT to \$6.00

Financial news for FCSC dated on 2015-09-25: Fibrocell, Intrexon Offer Update on Regulation for FCX-007 for Treatment of RDEB

Financial news for FCSC dated on 2015-08-06: Fibrocell Science Reports Q2 Loss \$0.17 Vs Est Loss \$0.16, Sales \$137K vs Est \$90K

Financial news for FCSC dated on 2015-07-27: Ranadal Kirk Buys 975,987 Shares of Fibrocell Science @\$5.80/Share -Form 4

Financial news for FCSC dated on 2015-07-22: Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More

Financial news for FCSC dated on 2015-07-22: Fibrocell Prices 2.6M Offering At \$5.80/Share

Financial news for FCSC dated on 2015-07-21: Fibrocell Reports Proposed Public Offering

Financial news for FCSC dated on 2015-07-20: Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Financial news for FCSC dated on 2015-06-08: US Stock Futures Edge Lower; Sears Q1 Loss Narrows

Financial news for FCSC dated on 2015-06-08: Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa at European Society of Human Genetics

Financial news for FCSC dated on 2015-06-01: Fibrocell Appoints Michael F. Marino as Senior VP, General Counsel and Corporate Secretary

Financial news for FCSC dated on 2015-05-12: Fibrocell Granted Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Financial news for FCSC dated on 2015-03-18: Fibrocell Science Names Keith Goldan SVP, CFO

Financial news for FCSC dated on 2015-03-13: Earnings Scheduled For March 13, 2015

Financial news for FCSC dated on 2015-02-02: 7 U.S. Health Care Penny Stocks With Upside Potential Greater Than 100%

Financial news for FCSC dated on 2014-10-03: Fibrocell Science Appoints Kimberly Smith As Interim CFO

Financial news for FCSC dated on 2014-08-11: Fibrocell Scientific Q2 EPS -\$0.06

Financial news for FCSC dated on 2014-06-11: FDA Posts Orphan Drug Designation for Fibrocell's Bullosa Treatment

Financial news for FCSC dated on 2014-06-06: Fibrocell Science Shareholder Kirk Buys 400,000 Shares @\$2.90/Share -Form 4

Financial news for FCSC dated on 2014-05-20: Fibrocell Science Shares at Session Lows as Bloomberg Highlights Downgrade to Neutral at Griffin Securities

Financial news for FCSC dated on 2014-05-19: Fibrocell Science Reports Q1 Loss of \$0.35/Share, Says Will Restate Financials

Financial news for FCSC dated on 2014-04-16: Sub \$5 Stocks With Expected Return Of Over 50% In 2014: Investment Idea Of The Day

Financial news for FCSC dated on 2013-09-26: Morning Market Losers

Financial news for FCSC dated on 2013-09-25: Fibrocell Science Announces Proposed Public Offering of Common Stock

Financial news for FCSC dated on 2013-07-02: Fibrocell Science Extends Patent Protection for LAVIV(r) (azficel-T) Through 2031

Financial news for FCSC dated on 2011-10-03: Fibrocell Science, Inc. Announces Launch

of LAVIV

Financial news for FCSC dated on 2011-08-24: Tuesday's OTCBB Percentage Gainers: Sigma Labs, MOJO Ventures, Fibrocell Science, Teletouch Communications

Financial news for FCSC dated on 2011-08-15: Friday's OTC Percentage Gainers

Financial news for FCSC dated on 2011-08-03: Fibrocell Science, Inc. to Raise \$22.7 Million in Private Placement

Financial news for FCSC dated on 2011-06-22: UPDATE: Fibrocell Science, Inc. Announces FDA Approval for laViv

Financial news for FCSC dated on 2011-06-22: Fibrocell Sciences Rises Over 70% on FDA approval

Financial news for FCSC dated on 2011-06-22: UPDATE: Fibrocell Expected to Release laViv Approval PR at 9:15am